Samsung Biologics Achieves Record Revenue and Secures Largest Contract to Date

Record Revenue:
Samsung Biologics achieved a record annual revenue of 4.547 trillion won ($2.78 billion) in 2024, marking a 23% increase year-over-year35.

Largest Contract:
The company signed a contract manufacturing (CMO) agreement worth 1.7 trillion won ($1.24 billion) with an Asian pharmaceutical company, the largest deal in its history2.

Biosimilar Sales:
Samsung Bioepis, the biosimilar subsidiary, recorded revenue of 1.537 trillion won and an operating profit of 435.4 billion won, driven by expanded global market penetration of its biosimilar products13.

Growth Projections:
Samsung Biologics expects continued growth in 2025, projecting revenue to increase by 20 to 25% year-over-year, with a median estimate of 5.57 trillion won35.

Manufacturing Capacity:
The company's manufacturing capacity will reach a world-leading 784,000 liters upon the completion of its fifth plant, scheduled for April5.

Sources:

1. https://www.businesskorea.co.kr/news/articleView.html?idxno=234308

2. https://www.koreabiomed.com/news/articleView.html?idxno=25452

3. https://www.koreabiomed.com/news/articleView.html?idxno=26413

5. https://koreajoongangdaily.joins.com/news/2025-01-22/business/industry/Samsung-Biologics-posts-record-2024-thanks-to-biosimilar-sales/2228280